Short Interest in Onconetix, Inc. (NASDAQ:ONCO) Increases By 365.3%

Onconetix, Inc. (NASDAQ:ONCO) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 266,600 shares, a growth of 365.3% from the December 15th total of 57,300 shares. Currently, 7.6% of the company’s shares are sold short. Based on an average daily volume of 5,240,000 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Onconetix

A hedge fund recently raised its stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 562,691 shares of the company’s stock after purchasing an additional 256,612 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 76.04% of Onconetix worth $2,926,000 at the end of the most recent quarter. Institutional investors and hedge funds own 23.89% of the company’s stock.

Onconetix Price Performance

ONCO traded up $0.14 during trading on Monday, hitting $0.65. 8,528,678 shares of the company’s stock were exchanged, compared to its average volume of 8,374,555. Onconetix has a 1 year low of $0.32 and a 1 year high of $21.40. The stock has a 50 day moving average price of $0.88 and a 200 day moving average price of $3.80.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.